JPWO2020113164A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020113164A5
JPWO2020113164A5 JP2021530200A JP2021530200A JPWO2020113164A5 JP WO2020113164 A5 JPWO2020113164 A5 JP WO2020113164A5 JP 2021530200 A JP2021530200 A JP 2021530200A JP 2021530200 A JP2021530200 A JP 2021530200A JP WO2020113164 A5 JPWO2020113164 A5 JP WO2020113164A5
Authority
JP
Japan
Prior art keywords
seq
nos
immunoglobulin
domain
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021530200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022510218A5 (https=
JP2022510218A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063854 external-priority patent/WO2020113164A1/en
Publication of JP2022510218A publication Critical patent/JP2022510218A/ja
Publication of JP2022510218A5 publication Critical patent/JP2022510218A5/ja
Publication of JPWO2020113164A5 publication Critical patent/JPWO2020113164A5/ja
Priority to JP2024133895A priority Critical patent/JP2024174865A/ja
Pending legal-status Critical Current

Links

Images

JP2021530200A 2018-11-30 2019-11-29 ヘテロ二量体四価特異性抗体およびこれらの使用 Pending JP2022510218A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024133895A JP2024174865A (ja) 2018-11-30 2024-08-09 ヘテロ二量体四価特異性抗体およびこれらの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862774111P 2018-11-30 2018-11-30
US62/774,111 2018-11-30
US201962794523P 2019-01-18 2019-01-18
US62/794,523 2019-01-18
PCT/US2019/063854 WO2020113164A1 (en) 2018-11-30 2019-11-29 Heterodimeric tetravalency and specificity antibody compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024133895A Division JP2024174865A (ja) 2018-11-30 2024-08-09 ヘテロ二量体四価特異性抗体およびこれらの使用

Publications (3)

Publication Number Publication Date
JP2022510218A JP2022510218A (ja) 2022-01-26
JP2022510218A5 JP2022510218A5 (https=) 2022-12-05
JPWO2020113164A5 true JPWO2020113164A5 (https=) 2022-12-05

Family

ID=70853677

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530200A Pending JP2022510218A (ja) 2018-11-30 2019-11-29 ヘテロ二量体四価特異性抗体およびこれらの使用
JP2024133895A Pending JP2024174865A (ja) 2018-11-30 2024-08-09 ヘテロ二量体四価特異性抗体およびこれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024133895A Pending JP2024174865A (ja) 2018-11-30 2024-08-09 ヘテロ二量体四価特異性抗体およびこれらの使用

Country Status (6)

Country Link
US (1) US20220098329A1 (https=)
EP (1) EP3902834A4 (https=)
JP (2) JP2022510218A (https=)
AU (1) AU2019387482A1 (https=)
CA (1) CA3121168A1 (https=)
WO (1) WO2020113164A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US20230248825A1 (en) 2020-07-24 2023-08-10 Cellectis S.A. T-cells expressing immune cell engagers in allogenic settings
WO2022032006A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb binding molecules and methods of use
JP7743500B2 (ja) 2020-08-05 2025-09-24 シンセカイン インコーポレイテッド Ｉｌ１０受容体結合性分子および使用方法
WO2022032045A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. IL10Rα/IL2Rγ SYNTHETIC CYTOKINES
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
WO2022056490A1 (en) * 2020-09-14 2022-03-17 Vor Biopharma, Inc. Chimeric antigen receptors for treatment of cancer
CN117794568A (zh) * 2020-11-18 2024-03-29 纪念斯隆凯特琳癌症中心 抗gpa33多特异性抗体和其用途
US20240059781A1 (en) * 2021-01-06 2024-02-22 Tonix Pharma Limited Methods of inducing immune tolerance with modified anti-cd154 antibodies
WO2022150791A2 (en) * 2021-01-11 2022-07-14 Synthekine, Inc. Compositions and methods related to il2 receptor binding
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
JP2024519041A (ja) 2021-05-21 2024-05-08 セレクティス ソシエテ アノニム 固形腫瘍における癌関連線維芽細胞を調節することによるｔ細胞媒介性免疫療法の効力の増強
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2023055376A1 (en) * 2021-09-30 2023-04-06 Virtuoso Binco, Inc. Multispecific antibodies for targeting cd47 and icam1 and methods of use thereof
US20240415888A1 (en) * 2021-10-20 2024-12-19 Memorial Sloan Kettering Cancer Center Anti-tshr multi-specific antibodies and uses thereof
WO2023081818A1 (en) 2021-11-05 2023-05-11 American Diagnostics & Therapy, Llc (Adxrx) Monoclonal antibodies against carcinoembryonic antigens, and their uses
EP4434548A1 (en) 2021-11-15 2024-09-25 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
WO2023138579A1 (zh) * 2022-01-21 2023-07-27 和铂医药美国股份有限公司 抗b7-h7抗体或其抗原结合片段及制备方法和应用
CN114685609B (zh) * 2022-04-11 2023-04-14 东北农业大学 一种超短自组装抗菌肽fwr及其制备方法与应用
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
CN118146376B (zh) * 2024-05-09 2024-07-05 成都微芯新域生物技术有限公司 Hla-g抗体及其制备方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US7070995B2 (en) * 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
EP2280997A2 (en) * 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
DK3323830T3 (da) * 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center Anti-gd2 antibodies
PL2635607T3 (pl) * 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
DK2714733T3 (da) * 2011-05-21 2019-05-06 Macrogenics Inc Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
EP2903691B1 (en) * 2012-10-05 2019-05-22 F.Hoffmann-La Roche Ag Methods for diagnosing and treating inflammatory bowel disease
TW201444872A (zh) * 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
BR112015023752B1 (pt) * 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
RU2714733C2 (ru) * 2013-03-15 2020-02-19 Мемориал Слоан-Кеттеринг Кэнсер Сентер Технологии мультимеризации
RU2687043C2 (ru) * 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN106459990B (zh) * 2014-02-07 2021-06-01 麦克马斯特大学 三功能t细胞抗原偶联物及其制备方法和用途
US10519248B2 (en) * 2014-07-25 2019-12-31 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
JP2018520650A (ja) * 2015-05-21 2018-08-02 アリゲーター・バイオサイエンス・アーベー 新規のポリペプチド
JP7269167B2 (ja) * 2016-10-14 2023-05-08 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド モジュラー四価二重特異性抗体プラットフォーム
CA3051484A1 (en) * 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
KR20190140943A (ko) * 2017-04-24 2019-12-20 메모리얼 슬로안 케터링 캔서 센터 항-cd33 항체 제제

Similar Documents

Publication Publication Date Title
JPWO2020113164A5 (https=)
Sedykh et al. Bispecific antibodies: design, therapy, perspectives
US12384850B2 (en) Guidance and navigation control proteins and method of making and using thereof
Qin et al. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
US20210206828A9 (en) Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
JP2022116230A (ja) 免疫療法用改変細胞
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
CN117285642A (zh) 制导和导航控制蛋白及其制备和使用方法
JP2023503943A (ja) がんを治療するための組み合わせ療法
JP2019525771A5 (https=)
TWI908779B (zh) 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
Guo et al. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
US20230002488A1 (en) Guidance and navigation control proteins and method of making and using thereof
Gu et al. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting
JPWO2019191120A5 (https=)
Huang et al. Multispecific, Multivalent Antibody‐Based Molecules Engineered on the DART® and TRIDENTTM Platforms
JPWO2019005640A5 (https=)
Fine et al. Mechanism-driven design of multispecific antibodies for targeted disease treatment
JPWO2019005639A5 (https=)
Li et al. Highlights of 2019 protein engineering summit (PEGS) in Boston, USA: advancing antibody-based cancer therapies to the clinic
WO2022178163A2 (en) Antibody-derived t cell activating technologies
Way et al. Bioinspired design of artificial signaling systems
CN117279633A (zh) 用于治疗癌症的组合疗法
US20260070977A1 (en) Anti-tigit/rhil-21 bifunctional fusion protein and use thereof
WO2025238157A1 (en) Multispecific binding agent suitable for use in cancer immune therapy